Jakub Wojcieszak. (2023). Aducanumab and lecanemab - two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer's disease. Polish Pharmaceutical Society.
Chicago Style (17th ed.) CitationJakub Wojcieszak. Aducanumab and Lecanemab - Two Novel Antibodies Against Pathologic Species of Amyloid Beta in the Treatment of Alzheimer's Disease. Polish Pharmaceutical Society, 2023.
MLA (9th ed.) CitationJakub Wojcieszak. Aducanumab and Lecanemab - Two Novel Antibodies Against Pathologic Species of Amyloid Beta in the Treatment of Alzheimer's Disease. Polish Pharmaceutical Society, 2023.
Warning: These citations may not always be 100% accurate.